Home Featured Page 44

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Buddhist Philosophy, Shadow Work, and Integrating a Psychedelic Experience

Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran,...

Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase...

“It Was Exactly What I Needed – Until I Was Arrested...

Rumination, the Default Mode Network, and How Neuroplasticity Changes Over Time

Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions,...

Why Psychedelic Practitioners Should be Trauma-Informed

BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD

Microdosing at Work: How Psychedelics are Creating Better Leaders

Somatic Therapy and Psychedelics: How Body-Centered Approaches Are Revolutionizing Trauma Treatment

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.